I just got my Dr. To get genetic testing on my mucin tumors. Came back I have KRAS mutation. Anyone else with this...

Appendiceal cancerNovember 13, 2026Written by Navis AI

Understanding Your KRAS Mutation in Appendiceal Cancer

I'm glad you advocated for genetic testing - that's an important step. KRAS mutations are found in approximately 40-50% of appendiceal mucinous tumors, so you're definitely not alone in having this finding.

What This Means for Treatment

The treatment landscape for KRAS-mutated appendiceal cancer is evolving, but I need to be direct with you: the specific KRAS variant matters significantly for treatment options.

The Key Question: Which KRAS Variant?

Your genetic testing report should specify which KRAS mutation you have. The most common variants in appendiceal cancer include:

  • KRAS G12D (most common - about 34% of KRAS mutations)
  • KRAS G12V (second most common)
  • KRAS G12C (rare in appendiceal cancer - only 1-2%)
  • KRAS G12R
  • Other variants (G13D, Q61, etc.)

Why this matters: The KRAS G12C variant has FDA-approved targeted therapies (adagrasib/Krazati and sotorasib), but this variant is very rare in appendiceal cancer. According to NCCN Guidelines, these KRAS G12C inhibitors have shown response rates of 21-42% in gastrointestinal cancers, though most data comes from colorectal and pancreatic cancers.

Tell us what’s going on with appendiceal cancer. 2 free answers, then a free account.

Current Treatment Approaches

For non-G12C KRAS mutations (which is likely your situation):

Standard chemotherapy remains the primary approach, but research is actively developing new options:

  1. Emerging KRAS-targeted therapies (clinical trials):

    • MRTX1133 - targets KRAS G12D specifically
    • RMC-6236 - targets multiple KRAS variants including G12D, G12V, G12R
    • ASP3082 - a protein degrader targeting KRAS G12D
    • Combination approaches with MEK inhibitors
  2. Chemotherapy - Still the backbone of treatment for inoperable disease:

    • FOLFOX or CAPOX regimens (often used in appendiceal cancer)
    • May work differently depending on your KRAS status
  3. Other biomarker-directed therapies - Your testing may have revealed additional actionable findings beyond KRAS

Critical Questions for Your Oncologist

  1. "Which specific KRAS variant do I have?" (G12D, G12V, G12C, etc.)

  2. "Are there clinical trials available for my specific KRAS mutation?"

    • Specifically ask about trials for appendiceal cancer or gastrointestinal cancers with your variant
  3. "Did my genetic testing reveal any other actionable mutations?"

    • MSI-high status (opens immunotherapy options)
    • BRCA1/2, PALB2 (opens PARP inhibitor options)
    • HER2 amplification
    • NTRK fusions (rare but highly treatable)
  4. "Should I get more comprehensive genomic testing?"

    • Tumor-only vs. tumor + germline testing
    • RNA sequencing (can find fusions that DNA testing misses)
  5. "What chemotherapy regimen do you recommend given my KRAS status?"

  6. "Would you recommend getting a second opinion at a center specializing in appendiceal cancer?"

    • Centers like MD Anderson, Memorial Sloan Kettering, or UCSF have appendiceal cancer expertise

The Bigger Picture

According to research presented at AACR conferences, KRAS has historically been considered "undruggable," but that's changing rapidly. The American Cancer Society notes that while KRAS mutations were once thought impossible to target, multiple new approaches are now in development.

For appendiceal cancer specifically: The treatment approach often depends more on whether your tumor is low-grade vs. high-grade mucinous, and whether you have peritoneal disease, than on KRAS status alone. KRAS status may help predict response to certain chemotherapies.

Next Steps

  1. Get the specific KRAS variant from your report - this is crucial
  2. Ask about comprehensive genomic profiling if you only had limited testing
  3. Search for clinical trials specific to your KRAS variant at ClinicalTrials.gov
  4. Consider a second opinion at an appendiceal cancer center of excellence
  5. Ask if your tumor should be tested for MSI/MMR status if not already done

The field is moving quickly - what wasn't available even 2 years ago may be available now or soon. Your oncologist will determine the most appropriate approach for YOUR specific case based on your complete clinical picture.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your next question, already answered

Tap to keep going. 2 free answers, then a free account.

Ask Navis about your case

That answer is general. Ask about your specific situation. Answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

  • Built by OpenCancer’s team of physician-scientists and cancer survivors.
  • Last updated November 13, 2026. Informational only — not a substitute for your oncology team.

Question asked:

I just got my Dr. [removed] get genetic testing on my mucin tumors. Came back I have KRAS mutation. Anyone else with this and was there a treatment option ? I am inoperable.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

More questions about Appendiceal cancer